AxioMed Spine

company

About

AxioMed Spine develops products that restore the spinal function of patients with degenerative spine diseases.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$2.75M
Industries
Health Care,Medical,Medical Device
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active

AxioMed Spine Corporation was formed in 2001 to develop products with a goal of restoring spinal function to patients with degenerative spine disease; thus advancing the standard of care beyond fusion and first generation artificial discs. Since its inception, AxioMed has secured over $34M in private equity financing from prestigious venture capitalists. The company´s Freedom® Lumbar Disc has been developed and clinical trials initiated. The company is headed by CEO, Patrick McBrayer, who joined AxioMed in early 2006. Mr. McBrayer along with founder and COO, James Kuras, lead an experienced management and development team with significant history and expertise in spinal implants, including early artificial disc development efforts. Company employment includes professionals with extensive spine and engineering experience. The team is augmented by a Medical Advisory Panel of surgeons from leading spine centers and universities. The company´s headquarters include product development and testing, clinical and regulatory affairs, and manufacturing. AxioMed will leverage its background in lumbar disc replacement with an ongoing development project for the cervical spine.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$20.75M
AxioMed Spine has raised a total of $20.75M in funding over 2 rounds. Their latest funding was raised on Feb 23, 2005 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 23, 2005 Series B $18M 1 Detail
Feb 10, 2003 Series A $2.75M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
AxioMed Spine is funded by 1 investors. CID Equity Partners are the most recent investors.
Investor Name Lead Investor Funding Round
CID Equity Partners Series B